Brii Bio­sciences stops man­u­fac­tur­ing Covid-19 an­ti­body com­bo, plans to with­draw EUA re­quest

Brii Bio­sciences said it will stop man­u­fac­tur­ing its Covid-19 an­ti­body com­bi­na­tion, sold in Chi­na, and is work­ing to with­draw its emer­gency use au­tho­riza­tion re­quest in the US, which it start­ed in Oc­to­ber 2021.

The Bei­jing and North Car­oli­na biotech com­mer­cial­ly launched the treat­ment in Chi­na last Ju­ly but is now ax­ing the work and re­vert­ing re­sources to oth­er “high-pri­or­i­ty pro­grams,” per a Fri­day up­date. The fo­cus now is name­ly he­pati­tis B vi­ral in­fec­tion, post­par­tum de­pres­sion and ma­jor de­pres­sive dis­or­ders.

To read Endpoints News become a free subscriber

Unlock this article instantly, along with access to limited free monthly articles and our suite of newsletters

SIGN UP LOG IN